GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PROCEPT BioRobotics Corp (NAS:PRCT) » Definitions » Cash Flow from Financing

PROCEPT BioRobotics (PROCEPT BioRobotics) Cash Flow from Financing : $170.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is PROCEPT BioRobotics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, PROCEPT BioRobotics paid $0.0 Mil more to buy back shares than it received from issuing new shares. It received $0.0 Mil from issuing more debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It received $0.0 Mil on other financial activities. In all, PROCEPT BioRobotics spent $0.0 Mil on financial activities for the three months ended in Mar. 2024.


PROCEPT BioRobotics Cash Flow from Financing Historical Data

The historical data trend for PROCEPT BioRobotics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PROCEPT BioRobotics Cash Flow from Financing Chart

PROCEPT BioRobotics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
26.53 106.77 262.12 3.61 167.80

PROCEPT BioRobotics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 2.43 162.12 2.87 2.59

PROCEPT BioRobotics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

PROCEPT BioRobotics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

PROCEPT BioRobotics's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $170.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PROCEPT BioRobotics  (NAS:PRCT) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

PROCEPT BioRobotics's issuance of stock for the three months ended in Mar. 2024 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

PROCEPT BioRobotics's repurchase of stock for the three months ended in Mar. 2024 was $0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

PROCEPT BioRobotics's net issuance of debt for the three months ended in Mar. 2024 was $0.0 Mil. PROCEPT BioRobotics received $0.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

PROCEPT BioRobotics's net issuance of preferred for the three months ended in Mar. 2024 was $0.0 Mil. PROCEPT BioRobotics paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

PROCEPT BioRobotics's cash flow for dividends for the three months ended in Mar. 2024 was $0.0 Mil. PROCEPT BioRobotics received $0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

PROCEPT BioRobotics's other financing for the three months ended in Mar. 2024 was $0.0 Mil. PROCEPT BioRobotics received $0.0 Mil on other financial activities.


PROCEPT BioRobotics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of PROCEPT BioRobotics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


PROCEPT BioRobotics (PROCEPT BioRobotics) Business Description

Traded in Other Exchanges
N/A
Address
900 Island Drive, Redwood, CA, USA, 94065
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
Executives
Alaleh Nouri officer: SVP, GEN COUNSEL, CORP. SEC. 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Kevin Waters officer: Senior VP, CFO 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Frederic H Moll director C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
Wood Morgan Colby director C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CA 94065
Reza Zadno director, officer: President, CEO 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Hisham Shiblaq officer: SVP, Commercial Operations C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Thomas M Krummel director C/O CALIFORNIA WATER SERVICE GROUP, 1720 N. FIRST STREET, SAN JOSE CA 95118
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 88 Llc 10 percent owner 55 RAILROAD AVE, GREENWICH CT 06830
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901